Medical Innovations and Future Trends Practice Questions

Q: A biotech company proposes using induced pluripotent stem cells (iPSCs) derived from patient fibroblasts to generate personalized cardiomyocytes for myocardial infarction treatment. What is the most significant ethical and technical challenge that must be addressed before clinical application?

Risk of teratoma formation and incomplete differentiation. ***Risk of teratoma formation and incomplete differentiation*** - Residual **undifferentiated pluripotent cells** pose a significant safety risk because they have the potential to grow into **tumors** (teratomas) after transplantation into the patient [1]. - Ensuring **purity** and complete differentiation into functional cardiomyocytes is the primary technical hurdle to avoid **oncogenic transformation** in clinical settings [1]. *Lack of vascularization in transplanted tissue* - While **diffusion limits** the survival of thick tissue grafts, this is an **engineering challenge** rather than a fundamental ethical or safety barrier like tumorigenicity. - Innovative approaches like **3D bioprinting** are being developed to address the blood supply issue for larger cardiac patches. *Rejection due to HLA mismatch* - A major advantage of using **patient-derived fibroblasts** to create **iPSCs** is that the resulting cells are **autologous**, meaning they are genetically identical to the recipient [1]. - Because the tissue is "self," the risk of **immunological rejection** and the need for immunosuppression are effectively eliminated. *High cost of production limiting accessibility* - Although the high cost and **resource-intensive** nature of personalized medicine present a public health challenge, it is classified as a **socioeconomic barrier**. - **Economic factors** are secondary to the immediate **clinical safety profile** required for regulatory approval and patient safety.

Q: An AI algorithm trained on chest X-rays from a single tertiary care center shows 95% accuracy in detecting tuberculosis. When deployed in a rural primary health center, accuracy drops to 68%. Which factor most likely explains this discrepancy?

Dataset shift and lack of external validation. ***Dataset shift and lack of external validation*** - This phenomenon occurs when an AI model is trained on a specific population (tertiary center) but fails to generalize to a different population with distinct characteristics, known as **dataset shift**. - The absence of **external validation** means the algorithm was not tested on diverse datasets before deployment, leading to poor **generalizability** in different clinical environments. *Hardware limitations at rural center* - While varying **image resolution** or file formats can affect AI performance, they generally do not cause a massive drop in accuracy if the model is robustly designed. - Hardware differences are a technical barrier rather than a fundamental flaw in the **algorithmic logic** or statistical generalizability. *Inadequate training of healthcare workers* - AI accuracy is a measure of the algorithm's **predictive performance** on given images, independent of the clinical skills of the human operators. - Training workers on how to use the interface does not change the **mathematical output** or sensitivity/specificity of the model itself. *Lower prevalence of tuberculosis in rural areas* - While **prevalence** significantly affects **Positive Predictive Value (PPV)**, accuracy as a metric is generally driven by the model's inherent sensitivity and specificity. - Even if prevalence shifted, the drop in overall accuracy suggests the model is failing to correctly identify **true negatives or true positives** because the rural data distribution differs from the training set.

Q: What is the underlying principle of CRISPR-Cas9 gene editing technology in treating inherited disorders?

Site-specific DNA cleavage and repair mechanism. ***Site-specific DNA cleavage and repair mechanism*** - CRISPR-Cas9 utilizes a **single guide RNA (sgRNA)** to direct the **Cas9 endonuclease** to a specific genomic location, where it creates a **double-strand break (DSB)** [1]. - The cell then repairs the break via **non-homologous end joining (NHEJ)** or **homology-directed repair (HDR)**, allowing for precise gene knockout or site-specific insertion of healthy DNA sequences [1]. *RNA interference to suppress gene expression* - **RNA interference (RNAi)** works at the post-transcriptional level by using **siRNA** or **miRNA** to degrade messenger RNA, not by editing the genome. - Unlike CRISPR, RNAi provides **transient suppression** of gene products rather than a permanent genetic correction. *Homologous recombination without cleavage* - Standard **homologous recombination** occurs naturally but is extremely inefficient for gene editing without an initial **enzymatic cleavage** to initiate the repair process [1]. - CRISPR-Cas9 specifically enhances editing efficiency by providing the necessary **double-strand break** that triggers cellular repair pathways [1]. *Viral vector-mediated gene insertion* - Traditional **gene therapy** often relies on **adenoviral** or **lentiviral vectors** to deliver functional gene copies that integrate randomly or remain episomal [2]. - While CRISPR can use viral delivery, its core principle is **precision editing** of the endogenous gene rather than just the addition of exogenous genetic material [1].

Q: Which technology is currently approved by FDA for continuous glucose monitoring using subcutaneous sensors?

Flash glucose monitoring. ***Flash glucose monitoring*** - **Flash glucose monitoring (FGM)**, such as the FreeStyle Libre system, is **FDA-approved** and uses a **subcutaneous sensor** to measure glucose in the **interstitial fluid**. [1] - This technology provides real-time data and trends, significantly reducing the need for routine **fingerstick calibrations** in diabetes management. [2] *Quantum dot sensors* - **Quantum dot sensors** are an emerging nanotechnology being researched for **fluorescence-based** glucose sensing but are not yet standard **FDA-approved** clinical practice. - Currently, this technology remains primarily in the **experimental stage** and lacks the widespread clinical verification of subcutaneous CGM systems. *Raman spectroscopy* - **Raman spectroscopy** is a **non-invasive** optical technique that measures glucose through the skin using light scattering; it does not utilize **subcutaneous sensors**. - While promising for a painless experience, it faces challenges with **accuracy** and environmental interference and is not currently **FDA-approved** for continuous monitoring. *Optical coherence tomography* - **Optical coherence tomography (OCT)** is an optical imaging modality used to detect changes in skin tissue properties related to glucose levels **non-invasively**. - It is not a **subcutaneous sensor** technology and has not reached the **FDA approval** status required for mainstream clinical continuous glucose monitoring.

Question 1

A hospital implements blockchain technology for maintaining electronic health records. Compared to traditional centralized database systems, what is the primary advantage that justifies this innovation from a healthcare quality perspective?

Accepted Answer

Enhanced data integrity through immutable distributed ledger

Answer

Faster data retrieval for clinical decision-making

Answer

Reduced storage costs due to distributed architecture

Answer

Simplified user interface for healthcare providers

Question 2

A biotech company proposes using induced pluripotent stem cells (iPSCs) derived from patient fibroblasts to generate personalized cardiomyocytes for myocardial infarction treatment. What is the most significant ethical and technical challenge that must be addressed before clinical application?

Accepted Answer

Risk of teratoma formation and incomplete differentiation

Answer

Lack of vascularization in transplanted tissue

Answer

Rejection due to HLA mismatch

Answer

High cost of production limiting accessibility

Question 3

An AI algorithm trained on chest X-rays from a single tertiary care center shows 95% accuracy in detecting tuberculosis. When deployed in a rural primary health center, accuracy drops to 68%. Which factor most likely explains this discrepancy?

Accepted Answer

Dataset shift and lack of external validation

Answer

Hardware limitations at rural center

Answer

Inadequate training of healthcare workers

Answer

Lower prevalence of tuberculosis in rural areas

Question 4

What is the underlying principle of CRISPR-Cas9 gene editing technology in treating inherited disorders?

Accepted Answer

Site-specific DNA cleavage and repair mechanism

Answer

RNA interference to suppress gene expression

Answer

Homologous recombination without cleavage

Answer

Viral vector-mediated gene insertion

Question 5

How does artificial intelligence-based clinical decision support system differ from traditional rule-based systems in predicting sepsis?

Accepted Answer

Applies machine learning algorithms to identify complex patterns

Answer

Uses static threshold values for vital parameters

Answer

Functions independently without continuous data input

Answer

Relies only on laboratory values for diagnosis

Question 6

What is the mechanism of action of CAR-T cell therapy used in hematological malignancies?

Accepted Answer

Genetically modified T cells targeting specific tumor antigens

Answer

Checkpoint inhibition leading to T cell activation

Answer

Direct cytotoxic effect through antibody-dependent cellular cytotoxicity

Answer

Monoclonal antibody binding to tumor cells

Question 7

Which technology is currently approved by FDA for continuous glucose monitoring using subcutaneous sensors?

Accepted Answer

Flash glucose monitoring

Answer

Quantum dot sensors

Answer

Raman spectroscopy

Answer

Optical coherence tomography

Medical Innovations and Future Trends — MCQs

Medical Innovations and Future Trends — MCQs

On this page

Practice by Chapter

Want unlimited practice?